---
title: "New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293757164.md"
description: "Jersey City, New Jersey - Organon has recently unveiled an analysis of Phase 3 pooled data for VTAMA (tapinarof) cream, 1%, demonstrating early and consistent improvements in eczema patients across various age groups. This analysis presents promising results for the medication, showcasing its effectiveness in treating eczema. This is a significant development in the field of dermatology, highlighting the potential of VTAMA cream in providing relief to individuals suffering from eczema."
datetime: "2026-07-24T12:08:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293757164.md)
  - [en](https://longbridge.com/en/news/293757164.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293757164.md)
generator: "portal-rs"
---

# New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

Jersey City, New Jersey - Organon has recently unveiled an analysis of Phase 3 pooled data for VTAMA (tapinarof) cream, 1%, demonstrating early and consistent improvements in eczema patients across various age groups. This analysis presents promising results for the medication, showcasing its effectiveness in treating eczema. This is a significant development in the field of dermatology, highlighting the potential of VTAMA cream in providing relief to individuals suffering from eczema.

### Related Stocks

- [OGN.US](https://longbridge.com/en/quote/OGN.US.md)

## Related News & Research

- [Asahi Kasei Therapeutics starts Japan Phase II trial of Cresemba in pediatric patients](https://longbridge.com/en/news/298854671.md)
- [Luz Saúde launches SKYPS sarilumab trial in children with systemic juvenile idiopathic arthritis](https://longbridge.com/en/news/299019803.md)
- [Comoto Drives $100,000 Fundraising Effort for Pediatric Brain Tumor Foundation](https://longbridge.com/en/news/298512275.md)
- [Is Novo Nordisk (CPSE:NOVO B) Cheap On New Childhood Obesity Trial Data?](https://longbridge.com/en/news/298732114.md)
- [BridgeBio posts PROPEL 3 Phase 3 infigratinib data in children with achondroplasia presentation](https://longbridge.com/en/news/298422109.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**